Company Encyclopedia
View More
name
NewcelX
NCEL.US
NewcelX Ltd., a biotechnology company, engages in developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company was founded in 2008 and is headquartered in Zurich, Switzerland.
1.875 T
NCEL.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    NewcelX Appoints Jeremy Shefner to Scientific Advisory Board

    NewcelX AG has appointed Prof. Jeremy Shefner, MD, PhD, to its Scientific Advisory Board. He will provide strategic guidance for ALS programs and support the integration of neuromuscular and neurodegenerative disease expertise into NewcelX’s cell therapy and neuroscience platform.

    Reuters·
    US
    NCEL
    -4.83%
    Reuters·
    US
    NCEL
    -4.83%

    NewcelX Announces New CFO Appointment Following Merger

    NewcelX Ltd. has appointed Mr. Omri Hagai as its new Chief Financial Officer, effective December 10, 2025, following the resignation of interim CFO Mr. Uri Ben Or. This change comes after the merger between NLS Pharmaceutics Ltd. and Kadimastem Ltd. Mr. Hagai's extensive experience in public companies is expected to enhance NewcelX's financial leadership. The company currently has a market cap of $2M and an average trading volume of 180,091.

    Tip Ranks·
    US
    NCEL
    -4.83%
    Tip Ranks·
    US
    NCEL
    -4.83%

    07:00 ET NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board

    NewcelX Ltd. (NASDAQ: NCEL) has appointed Professor Tamir Ben-Hur, a leading neurologist, to its Scientific Advisory Board. Prof. Ben-Hur, known for his expertise in neuroimmunology and regenerative medicine, expressed enthusiasm for contributing to NewcelX's mission of advancing therapies for neurodegenerative diseases. The company's CEO, Ronen Twito, highlighted this appointment as a significant endorsement of NewcelX's scientific foundation and its commitment to developing innovative treatments for conditions like ALS and Type 1 Diabetes.

    prnewswire·
    US
    NCEL
    -4.83%
    prnewswire·
    US
    NCEL
    -4.83%

    NewcelX Unveils Strategic Initiatives and Clinical Advancements

    NewcelX Ltd. has announced strategic initiatives and clinical advancements in a letter to shareholders dated November 4, 2025. The company is progressing with clinical trials for its assets, including AstroRx® for ALS and IsletRx for diabetes. Following its merger with NLS Pharmaceutics and Kadimastem, NewcelX is in a stronger financial position to achieve significant milestones. The company focuses on developing therapies for neurodegenerative and metabolic diseases, with a current market cap of $2.19M and an average trading volume of 169,817.

    Tip Ranks·
    US
    NCEL
    -4.83%
    Tip Ranks·
    US
    NCEL
    -4.83%

    NLS Pharmaceutics and Kadimastem merge to form NewcelX

    NLS Pharmaceutics and Kadimastem have merged to create NewcelX, a Swiss biopharmaceutical company focused on neurodegenerative and metabolic diseases. The merger involved raising approximately $9 million through equity financing and a $25 million Equity Line of Credit. NewcelX plans to initiate a Phase 2a clinical study in ALS and expand its therapeutic pipeline over the next year.

    Reuters·
    US
    NCEL
    -4.83%
    US
    NLSP
    0.00%
    Reuters·
    US
    NCEL
    -4.83%
    US
    NLSP
    0.00%